Advertisement

Latest News

Asundexian’s FDA Approval Opens Doors for Future Antithrombotic Therapies

3 hours ago

Mike Sharma, MD, MSc, discusses how asundexian’s approval revolutionizes secondary stroke prevention – and may provide a pathway to treat many more conditions.

Diabetes Dialogue: OPTIMAL-DIABETES, Survodutide, and Orforglipron at AHA 2026

6 hours ago

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.

Diabetes Dialogue: Tubeless Mobi Clearance, CGM Choice, and Eversense Freedom

7 hours ago

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss tubeless Mobi's FDA clearance, CVS Caremark's CGM formulary shift, and a transmitter-free implant.

Microbiome Therapies Show Potential in Hepatic Encephalopathy

8 hours ago

Patricia Bloom, MD, examines microbiome therapies for hepatic encephalopathy, FMT findings, and challenges in HE drug development.

Treatment Gaps Persist in Hepatic Encephalopathy Despite Standard Care

8 hours ago

Patricia Bloom, MD, discusses treatment gaps in hepatic encephalopathy and the role of adjunctive therapies in 2026 ACG guidance.

Advertisement
Advertisement